BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...H. Lundbeck A/S (CSE:LUN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK); and Xadago safinamide from Newron Pharmaceuticals S.p.A....
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

...percentage of company's posting declines, at 16%. The biggest decline was a 68% drop by Newron Pharmaceuticals S.p.A....
...EMD-128130) NC318 NC410 Tepezza, teprotumumab (HZN-001, RV001, r1507, rg1507) Moderna Inc. Inovio Pharmaceuticals Inc. Novavax Inc. Celldex Therapeutics Inc. Biogen Inc. Novocure Ltd. NextCure Inc. Progenity Inc. Newron Pharmaceuticals S.p.A. Eli...
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

...The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but...
...near its cash position -- a sign that investors see little value in what remains. Newron Pharmaceuticals S.p.A....
...129 patient study was percentage reduction in episodes of apnea during waking time vs. placebo. Newron...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...HER2-positive breast cancer previously treated with anti-HER2-targeted therapy Submit BLA 2H19 Merck KGaA (Xetra:MRK) / Newron Pharmaceuticals S.p.A....
BioCentury | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

...Patent in the U.S." ). Animal data prompts Newron to delay pivotal trial of antipsychotic Newron Pharmaceuticals S.p.A....
...to treat schizophrenia at FDA's request to complete additional short-term studies in rats and humans. Newron...
...RGH-188 (Compound #), MP-214 (Compound #), cariprazine (Generic) Fondazione Telethon Gedeon Richter plc Hansoh Pharmaceutical Group Co. Ltd. Juvenescence Ltd. Newron Pharmaceuticals S.p.A. Orchard...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...NYSE:JNJ) Zejula niraparib Castration-resistant prostate cancer Submit regulatory applications globally 2019 Merck KGaA (Xetra:MRK) / Newron Pharmaceuticals S.p.A....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...with severe burns Top-line Ph III DETECT data YE18 Meiji Seika Pharma Co. Ltd. / Newron Pharmaceuticals S.p.A....
BioCentury | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

...commercialize safinamide in Japan. Meiji Seika has rights to the drug in Asian territories from Newron Pharmaceuticals S.p.A....
...as a reversible monoamine oxidase B (MAO-B) and dopamine reuptake inhibitor while reducing glutamatergic activity. Newron Pharmaceuticals S.p.A....
...Status: Preliminary Phase II/III data Milestone: Submit MAA (2018) Chris Lieu safinamide Xadago Eisai Co. Ltd. Meiji Seika Pharma Co. Ltd. Newron Pharmaceuticals S.p.A. Monoamine...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...1H18 Nektar Therapeutics (NASDAQ:NKTR) NKTR-214 plus Opdivo nivolumab Solid tumors Ph Ib/II PIVOT-2 data June Newron Pharmaceuticals S.p.A....
...U.S. (Japan, South Korea in 2015) Neurocrine Biosciences Inc. (NASDAQ:NBIX) Ingrezza valbenazine Tardive dyskinesia U.S. Newron Pharmaceuticals S.p.A....
BioCentury | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...a Phase II trial of the non-steroidal selective androgen receptor modulator (SARM) in late 2018. Newron Pharmaceuticals S.p.A....
...Inc. (NASDAQ:GTXI), Memphis, Tenn. Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Jennie Walters enobosarm GTx-024 KD025 sarizotan Selective androgen receptor modulator tesevatinib TX-004HR XL647 Aisling Capital GTx Inc. Kadmon Holdings Inc. Newron Pharmaceuticals S.p.A. TherapeuticsMD...
Items per page:
1 - 10 of 241
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...H. Lundbeck A/S (CSE:LUN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK); and Xadago safinamide from Newron Pharmaceuticals S.p.A....
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

...percentage of company's posting declines, at 16%. The biggest decline was a 68% drop by Newron Pharmaceuticals S.p.A....
...EMD-128130) NC318 NC410 Tepezza, teprotumumab (HZN-001, RV001, r1507, rg1507) Moderna Inc. Inovio Pharmaceuticals Inc. Novavax Inc. Celldex Therapeutics Inc. Biogen Inc. Novocure Ltd. NextCure Inc. Progenity Inc. Newron Pharmaceuticals S.p.A. Eli...
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

...The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but...
...near its cash position -- a sign that investors see little value in what remains. Newron Pharmaceuticals S.p.A....
...129 patient study was percentage reduction in episodes of apnea during waking time vs. placebo. Newron...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...HER2-positive breast cancer previously treated with anti-HER2-targeted therapy Submit BLA 2H19 Merck KGaA (Xetra:MRK) / Newron Pharmaceuticals S.p.A....
BioCentury | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

...Patent in the U.S." ). Animal data prompts Newron to delay pivotal trial of antipsychotic Newron Pharmaceuticals S.p.A....
...to treat schizophrenia at FDA's request to complete additional short-term studies in rats and humans. Newron...
...RGH-188 (Compound #), MP-214 (Compound #), cariprazine (Generic) Fondazione Telethon Gedeon Richter plc Hansoh Pharmaceutical Group Co. Ltd. Juvenescence Ltd. Newron Pharmaceuticals S.p.A. Orchard...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...NYSE:JNJ) Zejula niraparib Castration-resistant prostate cancer Submit regulatory applications globally 2019 Merck KGaA (Xetra:MRK) / Newron Pharmaceuticals S.p.A....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...with severe burns Top-line Ph III DETECT data YE18 Meiji Seika Pharma Co. Ltd. / Newron Pharmaceuticals S.p.A....
BioCentury | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

...commercialize safinamide in Japan. Meiji Seika has rights to the drug in Asian territories from Newron Pharmaceuticals S.p.A....
...as a reversible monoamine oxidase B (MAO-B) and dopamine reuptake inhibitor while reducing glutamatergic activity. Newron Pharmaceuticals S.p.A....
...Status: Preliminary Phase II/III data Milestone: Submit MAA (2018) Chris Lieu safinamide Xadago Eisai Co. Ltd. Meiji Seika Pharma Co. Ltd. Newron Pharmaceuticals S.p.A. Monoamine...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...1H18 Nektar Therapeutics (NASDAQ:NKTR) NKTR-214 plus Opdivo nivolumab Solid tumors Ph Ib/II PIVOT-2 data June Newron Pharmaceuticals S.p.A....
...U.S. (Japan, South Korea in 2015) Neurocrine Biosciences Inc. (NASDAQ:NBIX) Ingrezza valbenazine Tardive dyskinesia U.S. Newron Pharmaceuticals S.p.A....
BioCentury | Sep 29, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...a Phase II trial of the non-steroidal selective androgen receptor modulator (SARM) in late 2018. Newron Pharmaceuticals S.p.A....
...Inc. (NASDAQ:GTXI), Memphis, Tenn. Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Jennie Walters enobosarm GTx-024 KD025 sarizotan Selective androgen receptor modulator tesevatinib TX-004HR XL647 Aisling Capital GTx Inc. Kadmon Holdings Inc. Newron Pharmaceuticals S.p.A. TherapeuticsMD...
Items per page:
1 - 10 of 241